Evidence map›Paper›PMID 35435245›Full record

Observational studyEuropean journal of clinical investigation2022

Circulating suPAR associates with severity and in-hospital progression of COVID-19.

Athanasios Chalkias, Anargyros Skoulakis, Nikolaos Papagiannakis, Eleni Laou, Konstantinos Tourlakopoulos, Athanasios Pagonis, Anastasia Michou, Nicoletta Ntalarizou, Maria Mermiri, Dimitrios Ragias and 7 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Novel inflammatory biomarkers in the prognosis of COVID-19.Therapeutic advances in respiratory disease
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Article
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Athanasios ChalkiasDepartment of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.ORCID https://orcid.org/0000-0002-7634-4665
Anargyros SkoulakisDepartment of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
Nikolaos PapagiannakisFirst Department of Neurology, Medical School, Aiginition University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Eleni LaouDepartment of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
Konstantinos TourlakopoulosDepartment of Respiratory Medicine, Faculty of Medicine, University of Thessaly, Larisa, Greece.
Athanasios PagonisDepartment of Respiratory Medicine, Faculty of Medicine, University of Thessaly, Larisa, Greece.
Anastasia MichouDepartment of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
Nicoletta NtalarizouDepartment of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
Maria MermiriDepartment of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
Dimitrios RagiasDepartment of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece.
Enrique Bernal-MorellInfectious Diseases Unit, Department of Internal Medicine, Hospital General Universitario Reina Sofía, Murcia, Spain.
Iria Cebreiros LópezDepartment of Laboratory Medicine, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Luis García de Guadiana-RomualdoDepartment of Laboratory Medicine, Hospital General Universitario Santa Lucía, Cartagena, Spain.
Jesper Eugen-OlsenDepartment of Clinical Research, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
Konstantinos GourgoulianisDepartment of Respiratory Medicine, Faculty of Medicine, University of Thessaly, Larisa, Greece.
Ioannis PantazopoulosDepartment of Emergency Medicine, Faculty of Medicine, University of Thessaly, Larisa, Greece.
SPARCOL Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 disease progression is characterized by hyperinflammation and risk stratification may aid in early aggressive treatment and advanced planning. The aim of this study was to assess whether suPAR and other markers measured at hospital admission can predict the severity of COVID-19.

methodsThe primary outcome measure in this international, multi-centre, prospective, observational study with adult patients hospitalized primarily for COVID-19 was the association of WHO Clinical Progression Scale (WHO-CPS) with suPAR, ferritin, CRP, albumin, LDH, eGFR, age, procalcitonin, and interleukin-6. Admission plasma suPAR levels were determined using the suPARnostic

resultsSeven hundred and sixty-seven patients, 440 (57.4%) males and 327 (42.6%) females, were included with a median age of 64 years. Log-suPAR levels significantly correlated with WHO-CPS score, with each doubling of suPAR increasing the score by one point (p < .001). All the other markers were also correlated with WHO-CPS score. Admission suPAR levels were significantly lower in survivors (7.10 vs. 9.63, 95% CI 1.47-3.59, p < .001). A linear model (SALGA) including suPAR, serum albumin, serum lactate dehydrogenase, eGFR, and age can best estimate the WHO-CPS score and survival. Combining all five parameters in the SALGA model can improve the accuracy of discrimination with an AUC of 0.80 (95% CI: 0.759-0.836).

conclusionssuPAR levels significantly correlated with WHO-CPS score, with each doubling of suPAR increasing the score by one point. The SALGA model may serve as a quick tool for predicting disease severity and survival at admission.

Indexed as

COVID-19Receptors, Urokinase Plasminogen ActivatorAdultBiomarkersFemaleHospitalsHumansMaleMiddle AgedPrognosisProspective StudiesBiomarkersReceptors, Urokinase Plasminogen ActivatorCOVID-19outcomesuPARWHO Clinical Progression Scale

Identifiers

PMID35435245
PMCPMC9111634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.